pfe:BiopharmaSegmentMember
2022-01-01
2022-12-31
0000078003
pfe:OncologyMember
pfe:IbranceMember
pfe:BiopharmaSegmentMember
2024-01-01
2024-12-31
0000078003
pfe:OncologyMember
pfe:IbranceMember
pfe:BiopharmaSegmentMember
2023-01-01
2023-12-31
0000078003
pfe:OncologyMember
pfe:IbranceMember
pfe:BiopharmaSegmentMember
2022-01-01
2022-12-31
0000078003
pfe:OncologyMember
pfe:XtandiMember
pfe:BiopharmaSegmentMember
2024-01-01
2024-12-31
0000078003
pfe:OncologyMember
pfe:XtandiMember
pfe:BiopharmaSegmentMember
2023-01-01
2023-12-31
0000078003
pfe:OncologyMember
pfe:XtandiMember
pfe:BiopharmaSegmentMember
2022-01-01
2022-12-31
0000078003
pfe:OncologyMember
pfe:PadcevMember
pfe:BiopharmaSegmentMember
2024-01-01
2024-12-31
0000078003
pfe:OncologyMember
pfe:PadcevMember
pfe:BiopharmaSegmentMember
2023-01-01
2023-12-31
0000078003
pfe:OncologyMember
pfe:PadcevMember
pfe:BiopharmaSegmentMember
2022-01-01
2022-12-31
0000078003
pfe:OncologyMember
pfe:AdcetrisMember
pfe:BiopharmaSegmentMember
2024-01-01
2024-12-31
0000078003
pfe:OncologyMember
pfe:AdcetrisMember
pfe:BiopharmaSegmentMember
2023-01-01
2023-12-31
0000078003
pfe:OncologyMember
pfe:AdcetrisMember
pfe:BiopharmaSegmentMember
2022-01-01
2022-12-31
0000078003
pfe:OncologyMember
pfe:OncologyBiosimilarsMember
pfe:BiopharmaSegmentMember
2024-01-01
2024-12-31
0000078003
pfe:OncologyMember
pfe:OncologyBiosimilarsMember
pfe:BiopharmaSegmentMember
2023-01-01
2023-12-31
0000078003
pfe:OncologyMember
pfe:OncologyBiosimilarsMember
pfe:BiopharmaSegmentMember
2022-01-01
2022-12-31
0000078003
pfe:OncologyMember
pfe:InlytaMember
pfe:BiopharmaSegmentMember
2024-01-01
2024-12-31
0000078003
pfe:OncologyMember
pfe:InlytaMember
pfe:BiopharmaSegmentMember
2023-01-01
2023-12-31
0000078003
pfe:OncologyMember
pfe:InlytaMember
pfe:BiopharmaSegmentMember
2022-01-01
2022-12-31
0000078003
pfe:OncologyMember
pfe:LorbrenaMember
pfe:BiopharmaSegmentMember
2024-01-01
2024-12-31
0000078003
pfe:OncologyMember
pfe:LorbrenaMember
pfe:BiopharmaSegmentMember
2023-01-01
2023-12-31
0000078003
pfe:OncologyMember
pfe:LorbrenaMember
pfe:BiopharmaSegmentMember
2022-01-01
2022-12-31
0000078003
pfe:OncologyMember
pfe:BosulifMember
pfe:BiopharmaSegmentMember
2024-01-01
2024-12-31
0000078003
pfe:OncologyMember
pfe:BosulifMember
pfe:BiopharmaSegmentMember
2023-01-01
2023-12-31
0000078003
pfe:OncologyMember
pfe:BosulifMember
pfe:BiopharmaSegmentMember
2022-01-01
2022-12-31
0000078003
pfe:OncologyMember
pfe:BraftoviMektoviMember
pfe:BiopharmaSegmentMember
2024-01-01
2024-12-31
0000078003
pfe:OncologyMember
pfe:BraftoviMektoviMember
pfe:BiopharmaSegmentMember
2023-01-01
2023-12-31
0000078003
pfe:OncologyMember
pfe:BraftoviMektoviMember
pfe:BiopharmaSegmentMember
2022-01-01
2022-12-31
0000078003
pfe:OncologyMember
pfe:TukysaMember
pfe:BiopharmaSegmentMember
2024-01-01
2024-12-31
0000078003
pfe:OncologyMember
pfe:TukysaMember
pfe:BiopharmaSegmentMember
2023-01-01
2023-12-31
0000078003
pfe:OncologyMember
pfe:TukysaMember
pfe:BiopharmaSegmentMember